EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells

Huina Su, Ruiqiong Ma, Dehui Su, Cheng Tan, Ye Zhu, Xin Yang

European Journal of Histochemistry · 21.04.2026 · 70 (2)

DOI: 10.4081/ejh.2026.4537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Histochemistry, online erschienen am 21.04.2026. Verfasst von Huina Su und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing. Hauptthemen laut MEDLINE: Cyclophosphamide, Primary Ovarian Insufficiency, Cellular Senescence, Quercetin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alkylating agents, particularly cyclophosphamide (CY), are known for their high toxicity, which can lead to iatrogenic premature ovarian insufficiency (POI) and infertility in young cancer survivors. Currently, effective prevention and treatment strategies remain limited. Given that chemotherapy induces cellular senescence, we investigated the therapeutic potential of dasatinib (D) and quercetin (Q), a senolytic combination known to eliminate senescent cells. Using a CY-induced murine model of ovarian injury, we found that CY treatment increased the accumulation of senescent cells in the ovaries. The resulting senescence-associated secretory phenotype (SASP) led to a deterioration of the ovarian microenvironment, characterized by increased follicular atresia and a decline in follicle quantity, ultimately culminating in POI. Our findings demonstrate that DQ therapy effectively mitigated CY-induced damage by clearing senescent cells and reducing SASP secretion. Clinically, DQ administration restored sex hormone levels and regularity of the estrous cycle, resulting in an overall increase in follicle numbers across all developmental stages. Furthermore, DQ treatment significantly normalized estrous cyclicity, restoring regular cycles in 60% of the CY+DQ mice compared to only ~15% in the CY-alone group (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamidePrimary Ovarian InsufficiencyCellular SenescenceQuercetinDasatinibSenotherapeuticsAnimalsFemaleMiceAntineoplastic Agents, Alkylating

Stichwörter der Autor:innen

Premature ovarian insufficiencycell senescencecyclophosphamidedasatinibquercetin

Substanzen

CyclophosphamideQuercetinDasatinibSenotherapeuticsAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing.

Zitieren

APA

Su, H., Ma, R., Su, D., Tan, C., Zhu, Y., & Yang, X. (2026). Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells. European Journal of Histochemistry, 70(2). https://doi.org/10.4081/ejh.2026.4537

Vancouver

Su H, Ma R, Su D, Tan C, Zhu Y, Yang X. Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells. European Journal of Histochemistry. 2026;70(2). doi:10.4081/ejh.2026.4537

BibTeX
@article{Su2026,
  author = {Su, Huina and Ma, Ruiqiong and Su, Dehui and Tan, Cheng and Zhu, Ye and Yang, Xin},
  title = {Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells},
  journal = {European Journal of Histochemistry},
  year = {2026},
  volume = {70},
  number = {2},
  doi = {10.4081/ejh.2026.4537}
}
Kostenlos starten →